Results 251 to 260 of about 50,773 (265)

Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis

Postgraduate Medicine, 2013
Srdan Verstovšek
exaly  

A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Clinical Lymphoma, Myeloma and Leukemia, 2015
Farhad Ravandi, Sara Dellasala, Srdan Verstovšek   +2 more
exaly  

Janus Kinase Inhibitors

2016
openaire   +1 more source

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis

Journal of Dermatology, 2020
Osamu Nemoto, Atsuyuki Igarashi, Hidehisa Saeki   +2 more
exaly  

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Journal of the American Academy of Dermatology, 2016
Kim A Papp, Steven R Feldman, Diamant Thaçi   +2 more
exaly  

Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera

JAAD Case Reports, 2019
Thomas H Leung, Misha Rosenbach
exaly  

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Lancet, The, 2018
Desirée Van Der Heijde, Xenofon Baraliakos, Lianne S Gensler   +2 more
exaly  

Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib

JAAD Case Reports, 2018
Sa Rang Kim, William Damsky, Peter Heald   +2 more
exaly  

Use of Janus Kinase Inhibitor Treatment for Palmoplantar Pustulosis: An Evidence-Based Review

Journal of Cutaneous Medicine and Surgery
Siddhartha Sood, Khalad Maliyar, Jorge R Georgakopoulos   +2 more
exaly  

Janus Kinase Inhibitors

openaire   +1 more source